This article was originally published in The Rose Sheet
Executive SummaryFine fragrance sales increased strong double-digits in the first half of the year, fueled by new wins and successes in the specialty retail segment and direct selling channels, Givaudan reports in six-month results issued Aug. 14. Consumer products sales advanced high single-digits on growth in all regions, according to the firm. Fragrance division sales, however, fell 3.3% to $412.2 mil. (CHF1=$.73) on a reported basis, while in local currencies, division sales increased 5.5%. Net sales dropped 7.4% to $1 bil. on a pro forma basis, assuming the acquisition of Nestle's flavor activities had taken place on Jan. 1, 2001, but were up 1.1% on a reported basis. Net profit for the six months fell 23.1% to $95.2 mil. on a pro forma basis...
You may also be interested in...
A maker of low-level LED light-therapy devices was cited by the US FDA for premarket, quality systems and Medical Device Reporting violations. It's just one of two device-related warning letters released by the agency this week.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 6)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this sixth installment of a 10-part series, experts David Elder and John McKay address communication between the front room – where investigators do the majority of their work – and the back room, used by company workers to fulfill investigator requests for documents, records and other information.
Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.